Phathom Pharmaceuticals Q1 2023 Earnings Report $6.96 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Phathom Pharmaceuticals EPS ResultsActual EPS-$0.89Consensus EPS -$1.34Beat/MissBeat by +$0.45One Year Ago EPSN/APhathom Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APhathom Pharmaceuticals Announcement DetailsQuarterQ1 2023Date5/10/2023TimeN/AConference Call ResourcesPress ReleasePHAT Earnings HistoryPowered by Phathom Pharmaceuticals Earnings HeadlinesNeedham & Company LLC Reaffirms Buy Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)January 12, 2025 | americanbankingnews.comPhathom Pharmaceuticals: Securing Long-term Exclusivity for Growth PotentialDecember 12, 2024 | markets.businessinsider.com[PDF] Free Cheat Sheet: How to build a dividend portfolio Would you like a simple set of guidelines for building a rock solid dividend portfolio? Including the two specific tickers I just put $50k into? Well, it’s all included in these FIVE Dividend Cheat SheetsJanuary 19, 2025 | ProsperityPub (Ad)Phathom Pharmaceuticals: Undervalued Opportunity with Strategic Moves for Extended ExclusivityDecember 12, 2024 | markets.businessinsider.comDo You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?December 12, 2024 | msn.comPhathom Pharmaceuticals: The Large Drop Is, Well, UnfathomableDecember 11, 2024 | seekingalpha.comSee More Phathom Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Phathom Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phathom Pharmaceuticals and other key companies, straight to your email. Email Address About Phathom PharmaceuticalsPhathom Pharmaceuticals (NASDAQ:PHAT), biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.View Phathom Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)HDFC Bank (1/21/2025)Charles Schwab (1/21/2025)Prologis (1/21/2025)3M (1/21/2025)Capital One Financial (1/21/2025)ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
